GLP-1 Drugs and Surgery: A 10-Year Study Just Changed the Conversation

GLP-1 Drugs and Surgery: A 10-Year Study Just Changed the Conversation

A new 10-year retrospective analysis just gave surgeons and GLP-1 users something real to talk about. If you're on semaglutide, tirzepatide, or any GLP-1 receptor agonist — and you're considering or recovering from an abdominal procedure — this research matters to you right now.

Most of the conversation around GLP-1s and surgery has focused on bariatric patients. This study looked somewhere different: people getting panniculectomies (skin removal surgery on the abdomen) who were not there for weight loss surgery. That's a key distinction, and the findings are sparking new questions about how these drugs affect surgical risk in a much broader population.

Important: I'm not a doctor. Everything I share here is based on published research and editorial analysis. Talk to your physician before making any changes to your health regimen — especially anything surgery-related.

---

The Bottom Line

• A 10-year retrospective study looked at GLP-1 receptor agonist use around the time of nonbariatric abdominal panniculectomy — a skin removal surgery unrelated to bariatric procedures.
• Patients on GLP-1 drugs showed meaningful differences in certain surgical outcome metrics compared to those not on these medications.
• The study adds to a growing body of evidence that perioperative GLP-1 use deserves specific attention from surgical teams — not just endocrinologists.
• Current guidance from major anesthesiology societies already recommends pausing GLP-1s before surgery due to aspiration risk; this study adds a new layer to that conversation.
• Actionable takeaway: If you're on a GLP-1 drug and have any surgery on the horizon, bring this research to your surgical team. Don't wait for them to ask.

---

Why a Panniculectomy Study Is Bigger News Than It Sounds

You might be wondering: why does a study about abdominal skin removal surgery matter to the average GLP-1 user?

Here's why. Bariatric surgery studies have dominated the GLP-1-plus-surgery conversation for years. Those patients are a specific population — they're already in a medically supervised weight loss program, their surgical teams expect GLP-1 use, and protocols are increasingly built around it.

Nonbariatric panniculectomy patients are different. Many of them lost significant weight on GLP-1 drugs and then pursued skin removal surgery as a separate, elective procedure. They may be on these medications long-term, not necessarily stopping them before their operation. Their surgical teams may not have the same level of experience managing GLP-1 users perioperatively.

That's the gap this study fills. According to the analysis published on PubMed, researchers reviewed a decade of patient data to understand how GLP-1 receptor agonist use around the time of surgery affected outcomes in this specific population. Ten years of data gives you statistical weight that a small case series simply cannot.

---

What the Research Actually Found

The study examined patients who underwent nonbariatric abdominal panniculectomy over a 10-year period, separating those who were on GLP-1 receptor agonists perioperatively from those who were not.

The researchers were looking at real surgical outcomes — things like wound complications, hospital readmission, and recovery metrics. This is not abstract pharmacology. This is: what actually happened to these patients after the procedure?

The findings suggest that GLP-1 use around the time of surgery was associated with differences in complication profiles. The specific nature and direction of those associations is what makes this study worth reading carefully rather than summarizing in a single sound bite — because the picture is more nuanced than "GLP-1s are good" or "GLP-1s are bad" before surgery.

What the study adds to the scientific record is real-world, long-horizon evidence in a population that has largely been overlooked in the perioperative literature. That matters.

---

The Aspiration Risk Issue: What You Probably Already Heard

If you follow GLP-1 news at all, you've probably seen headlines about aspiration risk and surgery. Here's the quick version.

GLP-1 receptor agonists slow gastric emptying. That's part of how they reduce appetite — food stays in the stomach longer, so you feel full. But when you go under general anesthesia, that slowed gastric emptying becomes a risk. If food or liquid is still sitting in your stomach when you're unconscious, it can move into your lungs. That's called aspiration, and it can be a serious surgical complication.

Because of this, the American Society of Anesthesiologists issued guidance recommending that patients on weekly GLP-1 injections hold their dose for at least a week before elective surgery. For daily formulations, the recommendation was one day. This guidance was updated in 2023 and has been influential but not universally implemented.

The panniculectomy study adds another dimension to this. It's not just about aspiration risk in the moment — it's about whether being on these drugs perioperatively shapes the overall trajectory of recovery. That's a longer and more complex question.

---

Why Surgeons Performing Elective Procedures Need to Know This

Panniculectomy is often the last step in a weight loss journey. Someone loses 80, 100, 150 pounds — sometimes with GLP-1 help — and then has excess skin removed. It's a real surgery with real recovery demands. It's not a quick outpatient procedure.

The surgeons performing these operations are plastic surgeons, not bariatric surgeons. They may have less familiarity with GLP-1 pharmacology and its perioperative implications. The anesthesiologists covering these cases may be working from general guidance rather than condition-specific protocols.

This study is, among other things, a signal to the surgical community that GLP-1 use needs to be part of the preoperative conversation for these patients — not an afterthought on the intake form.

According to a 2026 review of GLP-1 receptor agonists in the New England Journal of Medicine, these drugs are now being used across a wide range of metabolic conditions and increasingly in patients who may undergo unrelated surgeries. That means the perioperative management question is only going to grow.

---

What This Means If You're Currently on a GLP-1 Drug

Let's make this practical. You're on Ozempic, Wegovy, Mounjaro, Zepbound, or a compounded semaglutide or tirzepatide. You're planning or considering some kind of surgical procedure — maybe a panniculectomy after weight loss, maybe something entirely unrelated.

Here's what the current evidence suggests you should do:

Tell every member of your surgical team you're on a GLP-1. This sounds obvious, but it's frequently missed. GLP-1s aren't always flagged in medication reconciliation because some patients don't think of injectables the same way they think of daily pills. Your anesthesiologist needs to know.

Ask specifically about hold protocols. Based on current anesthesiology guidance, most surgical teams will ask you to hold your weekly injection for at least a week before the procedure. Know this ahead of time so you can plan your dosing schedule.

Discuss wound healing considerations. This is where the panniculectomy study is particularly relevant. GLP-1s have metabolic effects that may influence tissue healing. Researchers are still working out the full picture, but it's a conversation worth having with your surgical team rather than assuming it's been addressed.

Don't stop your medication without guidance. Stopping a GLP-1 abruptly before surgery without a plan can affect blood sugar control, especially in patients with type 2 diabetes. Any hold period should be coordinated with your prescribing physician.

---

The Bigger Signal: GLP-1 Research Is Expanding Fast

This panniculectomy study is one data point in an accelerating wave of GLP-1 research. The drugs that launched as diabetes treatments are now being studied across almost every organ system and clinical context.

Recent PubMed data shows active investigation into GLP-1 effects on dementia prevention, liver disease, kidney disease, cardiovascular events, and now surgical outcomes in nonbariatric populations.

The practical implication of this research explosion is that GLP-1 users need to be proactive. Guidelines are being written and rewritten in real time. What your surgeon knew about these drugs two years ago may already be outdated.

This isn't meant to alarm you. It's meant to empower you to ask better questions. The patients who get the best outcomes are the ones who show up to preoperative appointments with specific, informed questions — not the ones who assume their care team has everything covered.

---

What We Still Don't Know

In the interest of giving you the full picture, here's what the current research hasn't settled.

We don't yet have large-scale prospective trials on GLP-1 use and nonbariatric surgical outcomes. The 10-year retrospective design of the panniculectomy study is a strength in terms of real-world relevance, but retrospective studies have inherent limitations — they can't control for every variable, and they can't prove causation the way a randomized trial can.

We also don't have consensus on optimal hold periods across different surgery types and different GLP-1 formulations. Weekly injectables have different pharmacokinetics than daily ones, and the half-lives vary between drugs. Semaglutide has a notably long half-life compared to earlier GLP-1 agents, which affects how long it stays active in your system after the last dose.

Finally, we don't have clear protocols distinguishing between patients who are on GLP-1s for diabetes management versus those taking them primarily for weight loss. Those two groups may have different risk profiles in the surgical setting, and lumping them together may obscure important signals in the data.

These are the questions researchers are actively working on. Watch this space.

---

FAQ

Should I stop taking Ozempic or Wegovy before surgery? Current guidance from the American Society of Anesthesiologists suggests holding weekly GLP-1 injections for at least one week before elective surgery due to aspiration risk from slowed gastric emptying. You should not make this decision on your own — work with your prescribing doctor and your surgical team to coordinate timing, especially if you're using GLP-1s to manage blood sugar.

Does being on a GLP-1 drug increase surgical complications? The research is still developing. The 10-year panniculectomy study published in 2026 suggests that perioperative GLP-1 use is associated with differences in surgical outcomes, but the full picture is nuanced. Some effects may be protective, others may introduce new considerations. The key is making sure your surgical team is informed and prepared.

What is a panniculectomy and who gets one? A panniculectomy is a surgical procedure that removes excess skin and tissue from the lower abdomen. It's often pursued by people who have lost a significant amount of weight and are left with a pannus — a hanging fold of skin. It is distinct from a tummy tuck (abdominoplasty) and is not a bariatric (weight loss) surgery.

How long does it take for a GLP-1 drug to leave your system before surgery? This depends on the specific drug. Semaglutide (weekly injectable) has a half-life of approximately one week, meaning it takes several weeks to fully clear. Most anesthesiology guidance recommends holding weekly GLP-1s for at least one week before elective procedures, but your surgeon and anesthesiologist may recommend a longer hold period depending on your specific situation.

Is this research relevant to people on GLP-1s for weight loss, not diabetes? Yes. The growing population of GLP-1 users includes many people without diabetes who are using these medications for weight management. The perioperative considerations around gastric emptying, wound healing, and metabolic effects apply regardless of the original indication for the drug.

---

The Next Step

If you're on a GLP-1 drug and surgery is anywhere in your future — even months away — start the conversation now. Ask your prescribing doctor how to coordinate your medication schedule around the procedure. Ask your surgeon whether they've managed GLP-1 users before and what their hold protocol looks like.

You now have more context than most patients walking into those appointments. Use it.

The research is telling us that the perioperative period is a specific moment where GLP-1 pharmacology deserves careful attention. The panniculectomy study is a signal, not a scare. And knowing about it before you're three days out from surgery is exactly the kind of advantage that leads to better outcomes.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research — not medical recommendations.

---

Sources

1. Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis — PubMed, 2026
2. GLP-1 Receptor Agonists — Rosen & Ingelfinger — The New England Journal of Medicine, 2026
3. Tirzepatide versus semaglutide for prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes — PubMed, 2026
4. Impact of Tirzepatide on FIB-4 in Patients with Type 2 Diabetes — Internal Medicine (Tokyo), 2026
5. Next-generation therapeutics for diabetic kidney disease — Nature Reviews Nephrology, 2026
6. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events — PubMed, 2026